The prognosis depends mainly on the stage of the cancer. There does not seem to be any difference in survival between homologous and heterologous mixed mesodermal tumors.
Standard Treatment Hysterectomy , removal of tubes and ovaries on both sides, washings to check for malignant cells in the abdominal cavity and sampling of the pelvic and aortic lymph nodes on both sides.
After surgery, most women are treated with radiation therapy (total dose 4,000 to 5,000 cGy given in divided doses five days a week for five weeks) to the entire pelvis, including the upper vagina.
Chemotherapy is often used as an adjuvant therapy, although there is no documented proof of its benefit.
Investigational
• A clinical trial now being done by the Gynecologic Oncology Group is comparing ifosfamide with cisplatin
versus ifosfamide without cisplatin for the treatment of mixed mesodermal tumors. Thirty-five percent of
women respond to intravenous ifosfamide alone.
• Adriamycin in combination with DTIC or Cytoxan has been shown to be more effective than Adriamycin
alone for advanced disease.
• Vincristine and Cytoxan have also been used in combination with actinomycin-D or Adriamycin, with or
